Acamprosate and Quality of Life Assessment, Progress in alcoholism Management

Poldrougo, F. Lehert, Philippe [FUCAM]

(eng) Patients from five European countries were enrolled in an open, multicenter, prospective study designed to observe outcome in dependent drinkers treated for 6 months with acamprosate and psychosocial support. One-way fixed ANOVA and simultaneous stepwise linear regression analysis were used to identify potential predictors of quality of life at baseline and after treatment. The most important predictors of baseline quality of life were severity of alcohol dependence, employment status, psychiatric history, quantity and frequency of alcohol consumption, attendance at Alcoholics Anonymous, global alcohol health status, age, gender, and education. Health-related quality of life is severly impaired in dependent drinkers. Treatment with acamprosate and psychosocial support, by promoting abstinence, improves the quality of life profile to levels comparable to those observed in healthy individuals.

(fre) Une étude pragmatique de 1200 patients traités par acamprosaet et organisee sur 6 pays d'Europe met en évidence une augmentation de la qualité de vie à partir de 3 mois (anova, p<.001). L'utilisation du MOS-SF36 met en évidence une augmentation particulière concernant les critères de vie sociale et mentaux.